Literature DB >> 24743401

The diagnostic performance of urinary free cortisol is better than the cortisol:cortisone ratio in detecting de novo Cushing's syndrome: the use of a LC-MS/MS method in routine clinical practice.

Filippo Ceccato1, Giorgia Antonelli1, Mattia Barbot1, Marialuisa Zilio1, Linda Mazzai1, Rosalba Gatti1, Martina Zaninotto1, Franco Mantero1, Marco Boscaro1, Mario Plebani2, Carla Scaroni3.   

Abstract

OBJECTIVE: The Endocrine Society Clinical Guidelines recommend measuring 24-h urinary free cortisol (UFF) levels using a highly accurate method as one of the first-line screening tests for the diagnosis of Cushing's Syndrome (CS). We evaluated the performance of UFF, urinary free cortisone (UFE), and the UFF:UFE ratio, measured using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. SUBJECTS AND METHODS: The LC-MS/MS was used to analyze UFF and UFE levels in 43 surgically confirmed CS patients: 26 with Cushing's disease (CD, 16 de novo and ten recurrences), 11 with adrenal CS and six with ectopic CS; 22 CD patients in remission; 14 eu-cortisolemic CD patients receiving medical therapy; 60 non-CS patients; and 70 healthy controls. Sensitivity and specificity were determined in the combined groups of non-CS patients, healthy controls, and CD in remission.
RESULTS: UFF>170 nmol/24 h showed 98.7% specificity and 100% sensitivity for de novo CS, while sensitivity was 80% for recurrent CD patients, who were characterized by lower UFF levels. The UFF:UFE and UFF+UFE showed lower sensitivity and specificity than UFF. Ectopic CS patients had the highest UFF and UFF:UFE levels, which were normal in the CD remission patients and in those receiving medical therapy.
CONCLUSIONS: Our data suggest high diagnostic performance of UFF excretion measured using LC-MS/MS, in detecting de novo CS. UFF:UFE and UFF+UFE assessments are not useful in the first step of CS diagnosis, although high levels were found to be indicative of ectopic CS.
© 2014 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24743401     DOI: 10.1530/EJE-14-0061

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  17 in total

Review 1.  Cushing's Syndrome: Screening and Diagnosis.

Authors:  Filippo Ceccato; Marco Boscaro
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-05-09

2.  The activity of 11β-hydroxysteroid dehydrogenase type 2 enzyme and cortisol secretion in patients with adrenal incidentalomas.

Authors:  Valentina Morelli; Elisa Polledri; Rosa Mercadante; Volha Zhukouskaya; Serena Palmieri; Paolo Beck-Peccoz; Anna Spada; Silvia Fustinoni; Iacopo Chiodini
Journal:  Endocrine       Date:  2015-10-05       Impact factor: 3.633

3.  Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma.

Authors:  Filippo Ceccato; Mattia Barbot; Nora Albiger; Giorgia Antonelli; Marialuisa Zilio; Marco Todeschini; Daniela Regazzo; Mario Plebani; Carmelo Lacognata; Maurizio Iacobone; Franco Mantero; Marco Boscaro; Carla Scaroni
Journal:  Endocrine       Date:  2017-09-27       Impact factor: 3.633

Review 4.  Autonomous cortisol secretion in adrenal incidentalomas.

Authors:  Marta Araujo-Castro; Miguel Antonio Sampedro Núñez; Mónica Marazuela
Journal:  Endocrine       Date:  2019-03-07       Impact factor: 3.633

Review 5.  Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor.

Authors:  Marco Grasso; Marco Boscaro; Carla Scaroni; Filippo Ceccato
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-11-10

6.  First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS.

Authors:  F Ceccato; G Antonelli; A C Frigo; D Regazzo; M Plebani; M Boscaro; C Scaroni
Journal:  J Endocrinol Invest       Date:  2017-02-28       Impact factor: 4.256

7.  A venous thromboembolism risk assessment model for patients with Cushing's syndrome.

Authors:  Marialuisa Zilio; Linda Mazzai; Maria Teresa Sartori; Mattia Barbot; Filippo Ceccato; Viviana Daidone; Alessandra Casonato; Graziella Saggiorato; Franco Noventa; Laura Trementino; Paolo Prandoni; Marco Boscaro; Giorgio Arnaldi; Carla Scaroni
Journal:  Endocrine       Date:  2015-06-26       Impact factor: 3.633

Review 8.  Urine steroid profile as a new promising tool for the evaluation of adrenal tumors. Literature review.

Authors:  Marta Araujo-Castro; Pablo Valderrábano; Héctor F Escobar-Morreale; Felicia A Hanzu; Gregori Casals
Journal:  Endocrine       Date:  2020-11-21       Impact factor: 3.633

9.  Accuracy of immunoassay and mass spectrometry urinary free cortisol in the diagnosis of Cushing's syndrome.

Authors:  G Aranda; M Careaga; F A Hanzu; I Patrascioiu; P Ríos; M Mora; B Morales-Romero; W Jiménez; I Halperin; G Casals
Journal:  Pituitary       Date:  2016-10       Impact factor: 4.107

10.  Metyrapone treatment in Cushing's syndrome: a real-life study.

Authors:  Filippo Ceccato; Marialuisa Zilio; Mattia Barbot; Nora Albiger; Giorgia Antonelli; Mario Plebani; Sara Watutantrige-Fernando; Chiara Sabbadin; Marco Boscaro; Carla Scaroni
Journal:  Endocrine       Date:  2018-07-16       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.